Search

Search Constraints

You searched for: Author/Creator Milde, Till

Search Results

31. LGG-25. The first-in-class ERK inhibitor ulixertinib (BVD-523) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK inhibitors or senolytics. (3rd June 2022)

32. LGG-26. Predicting MAPK inhibitor sensitivity in pediatric low-grade gliomas with novel gene expression-derived signatures. (3rd June 2022)

33. LGG-27. Molecular implications of mitogen-activated protein kinase pathway inhibition by the MEK inhibitor trametinib in BRAF-fusion-driven pediatric pilocytic astrocytoma. (3rd June 2022)

34. LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION. (4th December 2020)

35. MBCL-06. RISK STRATIFICATION IMPROVEMENT OF THE HIT2000 AND I-HIT-MED COHORTS USING MOLECULAR SUBTYPES I-VIII OF GROUP 3/4 MEDULLOBLASTOMAS. (4th December 2020)

36. MBCL-21. GERMLINE ELONGATOR MUTATIONS IN SONIC HEDGEHOG MEDULLOBLASTOMA. (4th December 2020)

37. MBRS-12. INTERFERENCE WITH THE FUNCTION OF MYC IN GROUP 3 MEDULLOBLASTOMA. Issue 2 (22nd June 2018)

38. MBRS-12. INTERFERENCE WITH THE FUNCTION OF MYC IN GROUP 3 MEDULLOBLASTOMA. Issue 2 (22nd June 2018)

40. MBRS-65. CHEMI-GENOMIC ANALYSIS OF PATIENT-DERIVED XENOGRAFTS TO IDENTIFY PERSONALIZED THERAPIES FOR MEDULLOBLASTOMA. Issue 2 (22nd June 2018)